# Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

> **NCT00306475** · PHASE4 · COMPLETED · sponsor: **Northwestern University** · enrollment: 60 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Divalproex Sodium Extended-Release Tablets
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00306475
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306475, "Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00306475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*